| Name | Amitriptyline |
| Description | Amitriptyline (MK-230, N-750, Ro41575) is a tricyclic antidepressant (TCA) with analgesic properties. Amitriptyline is widely used to treat depression and neuropathic pain. |
| In vitro | Amitriptyline inhibits both serotonin transporter (SERT) and norepinephrine transporter (NET) with Ki of 3.45 nM and 13.3 nM, respectively. Amitriptyline is also an inhibitor of histamine receptor H1, histamine receptor H4, 5-HT2 and sigma 1 receptor with Ki of 0.5 nM, 7.31 nM, 235 nM and 287 nM, respectively. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 9.7 mg/mL (34.97 mM), Sonication is recommended.
|
| Keywords | σ1 | Sigmareceptor | Sigma receptor | SERT | norepinephrine transporter (NET) | HistamineReceptor | Histamine Receptor | H4 receptor | H1 receptor | Amitriptyline | 5HTReceptor | 5-HT2 | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Meclizine dihydrochloride | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | Lidocaine | Famotidine | 1,8-Cineole | Sodium butanoate | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |